Stevanato Group Sp A - Understand $stvn stock

$STVN Market Cap: $5.255 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$1.088B

TTM

Gross Margin

29.41%

TTM

Net Earnings

$122.5M

TTM

Current Assets

$869.7M

Q2 2024

Current Liabilities

$499.6M

Q2 2024

Current Ratio

174.09%

Q2 2024

Total Assets

$2.197B

Q2 2024

Total Liabilities

$872.9M

Q2 2024

Book Value

$1.324B

Q2 2024

Cash

$78.15M

Q2 2024

P/E

42.89

Sep 13, 2024 EST

Free Cash Flow

-$256.7M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019
Revenue	$1.085B	$983.7M	$843.9M	$662.0M	$536.5M
YoY Change	10.34%	16.56%	27.47%	23.39%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019
Revenue	$1.085B	$983.7M	$843.9M	$662.0M	$536.5M
Cost Of Revenue	$745.5M	$660.6M	$577.8M	$467.9M	$398.5M
Gross Profit	$339.9M	$319.8M	$266.1M	$194.2M	$138.0M
Gross Profit Margin	31.31%	32.51%	31.53%	29.33%	25.72%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019
Selling, General & Admin	$113.9M	$101.4M	$76.44M	$72.68M	$69.92M
YoY Change	12.28%	32.72%	5.17%	3.94%
% of Gross Profit	33.51%	31.72%	28.72%	37.43%	50.66%
Research & Development	$35.67M	$34.39M	$26.26M	$14.81M	$6.896M
YoY Change	3.74%	30.93%	77.33%	114.76%
% of Gross Profit	10.5%	10.75%	9.87%	7.63%	5.0%
Depreciation & Amortization	$78.48M	$64.82M	$56.38M	$54.10M	$46.22M
YoY Change	21.07%	14.97%	4.21%	17.06%
% of Gross Profit	23.09%	20.27%	21.19%	27.86%	33.49%
Operating Expenses	$35.67M	$34.39M	$103.4M	$91.07M	$75.80M
YoY Change	3.74%	-66.76%	13.58%	20.14%
Operating Profit	$304.2M	$285.4M	$162.7M	$103.1M	$62.22M
YoY Change	6.59%	75.46%	57.76%	65.72%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019
Interest Expense	$3.734M	$3.363M	$3.521M	-$4.492M	-$3.810M
YoY Change	11.03%	-4.49%	-178.38%	17.9%
% of Operating Profit	1.23%	1.18%	2.16%	-4.36%	-6.12%
Other Income/Expense, Net	-$226.0K	-$124.0K	-$73.00K	-$2.338M	-$3.696M
YoY Change	82.26%	69.86%	-96.88%	-36.74%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019
Pretax Income	$189.6M	$187.6M	$165.7M	$96.28M	$54.71M
YoY Change	1.04%	13.26%	72.08%	75.97%
Income Tax	$43.90M	$44.63M	$31.40M	$17.68M	$16.01M
% Of Pretax Income	23.15%	23.78%	18.96%	18.37%	29.26%
Net Earnings	$145.7M	$143.0M	$134.3M	$78.51M	$39.20M
YoY Change	1.87%	6.47%	71.08%	100.28%
Net Earnings / Revenue	13.42%	14.54%	15.92%	11.86%	7.31%
Basic Earnings Per Share
Diluted Earnings Per Share	$0.55	$0.54	$531.6K	$266.3K	$133.0K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019
Cash & Short-Term Investments	$73.98M	$262.3M	$438.3M	$157.1M	$126.7M
YoY Change	-71.8%	-40.14%	178.89%	24.03%
Cash & Equivalents	$69.60M	$228.7M	$411.0M	$115.6M	$85.39M
Short-Term Investments	$4.382M	$33.60M	$27.22M	$41.54M	$41.31M
Other Short-Term Assets					$1.000K
YoY Change
Inventory	$255.3M	$213.3M	$148.9M	$139.4M	$131.9M
Prepaid Expenses
Receivables	$485.2M	$326.0M	$232.9M	$169.4M	$162.9M
Other Receivables	$47.36M	$44.18M	$45.85M	$26.91M	$28.07M
Total Short-Term Assets	$861.9M	$845.8M	$866.0M	$492.8M	$449.6M
YoY Change	1.91%	-2.33%	75.73%	9.61%
Property, Plant & Equipment	$1.047B	$660.7M	$415.4M	$339.0M	$306.9M
YoY Change	58.43%	59.05%	22.53%	10.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$5.728M	$4.621M	$1.084M	$2.769M	$3.895M
YoY Change	23.96%	326.29%	-60.85%	-28.91%
Other Assets	$76.25M	$69.21M	$57.21M	$52.25M	$39.71M
YoY Change	10.17%	20.97%	9.49%	31.59%
Total Long-Term Assets	$1.210B	$813.9M	$552.9M	$475.2M	$432.6M
YoY Change	48.62%	47.22%	16.34%	9.85%
Total Assets	$2.072B	$1.660B	$1.419B	$968.0M	$882.2M
YoY Change
Accounts Payable	$277.8M	$239.2M	$164.8M	$118.7M	$95.05M
YoY Change	16.15%	45.14%	38.78%	24.92%
Accrued Expenses	$1.644M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$84.01M	$13.25M	$37.00K	$581.0K	$2.091M
YoY Change	534.24%	35697.3%	-93.63%	-72.21%
Long-Term Debt Due	$57.43M	$55.48M	$41.75M	$67.34M	$67.13M
YoY Change	3.51%	32.9%	-38.0%	0.31%
Total Short-Term Liabilities	$574.4M	$462.5M	$338.6M	$316.2M	$262.9M
YoY Change	24.19%	36.58%	7.1%	20.25%
Long-Term Debt	$255.2M	$598.4M	$201.6M	$294.1M	$305.4M
YoY Change	-57.36%	196.89%	-31.47%	-3.71%
Other Long-Term Liabilities	$99.77M	-$418.1M	$17.90M	$35.92M	$37.93M
YoY Change	-123.86%	-2436.26%	-50.18%	-5.3%
Total Long-Term Liabilities	$354.9M	$180.3M	$219.5M	$330.0M	$343.4M
YoY Change	96.81%	-17.83%	-33.51%	-3.88%
Total Liabilities	$939.0M	$663.6M	$576.8M	$657.5M	$616.7M
YoY Change	41.51%	15.05%	-12.28%	6.61%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Dividends

Stock Price

Market Cap: $5.2546 Billion

About Stevanato Group SpA

Stevanato Group SpA engages in the provision of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The company is headquartered in Piombino Dese, Padova and currently employs 5,635 full-time employees. The company went IPO on 2021-07-16. The firm delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The firm operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.

Industry: Surgical & Medical Instruments & Apparatus Peers: